Education
5 min read

How To Implement an AI Scribe in an Australian Practice

Published on
January 1, 2026
Contributors
David Danks
Subscribe to our newsletter
Read about our privacy policy.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

How To Implement an AI Scribe in an Australian Practice

Implementation at the practice level covers the decisions and processes that sit above the individual clinician workflow: contracting, consent at a practice-wide level, staged rollout, quality assurance, and the operational considerations that determine whether a deployment sticks or stalls.

This guide covers those considerations for an Australian practice implementing Lyrebird, with reference to the implementation lessons drawn from the Gold Coast Hospital and Health Service evaluation. The guide assumes the product decision has already been made.

For evaluation, see the Evaluating Ambient Documentation Vendors checklist.

Before contracting

Four things are worth confirming before signing a vendor agreement.

Data residency. Patient data processing and storage in Australia avoids the APP 8 offshore-transfer disclosure that would otherwise apply to every consult. Lyrebird processes and stores all data on Australian servers; see the compliance page for the full position.

TGA positioning. The August 2025 TGA guidance distinguishes documentation scribes from medical devices. A vendor should be able to state clearly which side of that line their product sits on, and if any diagnostic or treatment recommendation features are included, whether the product is ARTG-listed.

EMR integration depth. For practices on Bp Premier, Lyrebird offers the only AI scribe integration that Best Practice Software describes as "exclusive," developed in close partnership with Best Practice. See the Best Practice integration page for specifics. For other EMRs, the integration roadmap and current workflow should be confirmed.

Training data. Some free-tier products use patient conversations for model training. Lyrebird does not use customer data for model training, and this is confirmed in the contract.

Setting up consent at practice level

Consent for AI scribe use is required under three converging sources: the Australian Privacy Principles, TGA guidance, and medical defence organisation positions. At the practice level, the decision is how to obtain it consistently.

Most practices land on a combination: written consent captured at patient enrolment and retained as a persistent record, with a brief verbal reminder at the first consult where the scribe is used. Patients already enrolled at the point of rollout can be notified via letter, email, or SMS, with a verbal consent check at the next consult.

Consent wording should be agreed at the practice level so patients receive consistent information across different clinicians. Agreeing wording practice-wide also reduces the friction of individual clinicians working out their own approach under time pressure.

Staged rollout

Rolling out a scribe across all clinicians simultaneously tends to produce more friction than staged rollout. The GCHHS evaluation found that deployments anchored on a small group of early users, whose feedback informed wider rollout, produced better outcomes than broad simultaneous launches.

A practical sequence is two or three clinicians in the first month, the full practice in the second, with explicit feedback collection at the end of the first month. Clinicians who are keen volunteers tend to produce better early feedback than clinicians who have been nominated because they have the heaviest documentation load, although both cohorts become relevant to the wider rollout eventually.

Templates and the first fortnight

The single operational factor that most differentiates sustained time savings from plateaued ones, across the GCHHS lessons, is template adaptation in the first fortnight. Clinicians who upload a handful of their own existing notes so the scribe learns their structure, and who adjust recurring edits into template changes rather than re-making the same edit, see review times drop meaningfully over the first two weeks. Clinicians who skip this step see larger ongoing edit burden and smaller time savings.

At the practice level, the implication is that protected time for template work in the first fortnight is one of the higher-leverage investments in the deployment. A small amount of time per clinician in week one tends to compound significantly over the subsequent year.

Quality assurance

The GCHHS evaluation identified a quality assurance loop as one of the factors separating successful deployments from those that stalled. This does not need to be elaborate. A monthly review of a small sample of notes across the practice, with any recurring issues escalated to template adjustment or training, is sufficient.

The process matters because it makes scribe-related errors visible at a system level rather than only at the individual note level. Recurring mischaracterisations of a particular condition, drug class, or referral pathway show up in QA review before they show up in a medicolegal context, and template or prompt adjustments can be made accordingly.

For detail on quality governance questions to ask vendors, see the Evaluating Ambient Documentation Vendors checklist.

Ongoing vendor management

TGA guidance identifies review of software updates that could affect clinical behaviour as a specific responsibility. At the practice level, this is a light but real ongoing task: vendors should communicate material changes, and the practice should note them in the QA process. Lyrebird maintains a compliance page tracking regulatory and product changes.

Consent documentation should be periodically reviewed to ensure the wording still reflects what the product does, particularly if the product adds features over time.

Measuring impact

The most informative measures at the practice level are documentation time per consult, after-hours documentation time, and note quality on periodic review. These correspond directly to the metrics reported in the GCHHS evaluation.

Revenue and patient volume effects are downstream and depend on whether recovered time is redirected to additional consultations, reduced working hours, or administrative work.

Next steps

To trial Lyrebird directly, book a demo. For Bp Premier users, Lyrebird Free is available for all Bp Premier customers.

More Resources
Continue reading
Posts
The dangers of Copy Paste Scribes
Read More
Posts
How to use an AI medical scribe
Read More
Posts
December Product Updates
Read More
Announcement
Meet Dr. Ray Boyapati, Chief Clinical Officer
Read More
Announcement
Lyrebird Health Appoints Dr. Ray Boyapati to Chief Clinical Officer to Elevate the Standard of Clinical Care
Read More
Education
TGA Regulation and AI Scribes
Read More
Post
5 min read

How To Implement an AI Scribe in an Australian Practice

Published on
January 1, 2026
Contributors
David Danks
Subscribe to our newsletter
Read about our privacy policy.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

How To Implement an AI Scribe in an Australian Practice

Implementation at the practice level covers the decisions and processes that sit above the individual clinician workflow: contracting, consent at a practice-wide level, staged rollout, quality assurance, and the operational considerations that determine whether a deployment sticks or stalls.

This guide covers those considerations for an Australian practice implementing Lyrebird, with reference to the implementation lessons drawn from the Gold Coast Hospital and Health Service evaluation. The guide assumes the product decision has already been made.

For evaluation, see the Evaluating Ambient Documentation Vendors checklist.

Before contracting

Four things are worth confirming before signing a vendor agreement.

Data residency. Patient data processing and storage in Australia avoids the APP 8 offshore-transfer disclosure that would otherwise apply to every consult. Lyrebird processes and stores all data on Australian servers; see the compliance page for the full position.

TGA positioning. The August 2025 TGA guidance distinguishes documentation scribes from medical devices. A vendor should be able to state clearly which side of that line their product sits on, and if any diagnostic or treatment recommendation features are included, whether the product is ARTG-listed.

EMR integration depth. For practices on Bp Premier, Lyrebird offers the only AI scribe integration that Best Practice Software describes as "exclusive," developed in close partnership with Best Practice. See the Best Practice integration page for specifics. For other EMRs, the integration roadmap and current workflow should be confirmed.

Training data. Some free-tier products use patient conversations for model training. Lyrebird does not use customer data for model training, and this is confirmed in the contract.

Setting up consent at practice level

Consent for AI scribe use is required under three converging sources: the Australian Privacy Principles, TGA guidance, and medical defence organisation positions. At the practice level, the decision is how to obtain it consistently.

Most practices land on a combination: written consent captured at patient enrolment and retained as a persistent record, with a brief verbal reminder at the first consult where the scribe is used. Patients already enrolled at the point of rollout can be notified via letter, email, or SMS, with a verbal consent check at the next consult.

Consent wording should be agreed at the practice level so patients receive consistent information across different clinicians. Agreeing wording practice-wide also reduces the friction of individual clinicians working out their own approach under time pressure.

Staged rollout

Rolling out a scribe across all clinicians simultaneously tends to produce more friction than staged rollout. The GCHHS evaluation found that deployments anchored on a small group of early users, whose feedback informed wider rollout, produced better outcomes than broad simultaneous launches.

A practical sequence is two or three clinicians in the first month, the full practice in the second, with explicit feedback collection at the end of the first month. Clinicians who are keen volunteers tend to produce better early feedback than clinicians who have been nominated because they have the heaviest documentation load, although both cohorts become relevant to the wider rollout eventually.

Templates and the first fortnight

The single operational factor that most differentiates sustained time savings from plateaued ones, across the GCHHS lessons, is template adaptation in the first fortnight. Clinicians who upload a handful of their own existing notes so the scribe learns their structure, and who adjust recurring edits into template changes rather than re-making the same edit, see review times drop meaningfully over the first two weeks. Clinicians who skip this step see larger ongoing edit burden and smaller time savings.

At the practice level, the implication is that protected time for template work in the first fortnight is one of the higher-leverage investments in the deployment. A small amount of time per clinician in week one tends to compound significantly over the subsequent year.

Quality assurance

The GCHHS evaluation identified a quality assurance loop as one of the factors separating successful deployments from those that stalled. This does not need to be elaborate. A monthly review of a small sample of notes across the practice, with any recurring issues escalated to template adjustment or training, is sufficient.

The process matters because it makes scribe-related errors visible at a system level rather than only at the individual note level. Recurring mischaracterisations of a particular condition, drug class, or referral pathway show up in QA review before they show up in a medicolegal context, and template or prompt adjustments can be made accordingly.

For detail on quality governance questions to ask vendors, see the Evaluating Ambient Documentation Vendors checklist.

Ongoing vendor management

TGA guidance identifies review of software updates that could affect clinical behaviour as a specific responsibility. At the practice level, this is a light but real ongoing task: vendors should communicate material changes, and the practice should note them in the QA process. Lyrebird maintains a compliance page tracking regulatory and product changes.

Consent documentation should be periodically reviewed to ensure the wording still reflects what the product does, particularly if the product adds features over time.

Measuring impact

The most informative measures at the practice level are documentation time per consult, after-hours documentation time, and note quality on periodic review. These correspond directly to the metrics reported in the GCHHS evaluation.

Revenue and patient volume effects are downstream and depend on whether recovered time is redirected to additional consultations, reduced working hours, or administrative work.

Next steps

To trial Lyrebird directly, book a demo. For Bp Premier users, Lyrebird Free is available for all Bp Premier customers.

Keep reading

All posts
Questions about compliance?